BRPI0411114B8 - solução aquosa estável de eritropoetina humana, não contendo albumina de soro - Google Patents

solução aquosa estável de eritropoetina humana, não contendo albumina de soro

Info

Publication number
BRPI0411114B8
BRPI0411114B8 BRPI0411114A BRPI0411114A BRPI0411114B8 BR PI0411114 B8 BRPI0411114 B8 BR PI0411114B8 BR PI0411114 A BRPI0411114 A BR PI0411114A BR PI0411114 A BRPI0411114 A BR PI0411114A BR PI0411114 B8 BRPI0411114 B8 BR PI0411114B8
Authority
BR
Brazil
Prior art keywords
human erythropoietin
serum albumin
aqueous solution
stable aqueous
containing serum
Prior art date
Application number
BRPI0411114A
Other languages
English (en)
Inventor
Sung Jeh Hoon
Eon Kim Ji
Oh Jin-Seok
Chan Kwon Kyu
Jin Kim Myung
Joo Lee Seung
Young Choi Suk
Cheol Kang Young
Original Assignee
Lg Chemical Ltd
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0411114(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Chemical Ltd, Lg Life Sciences Ltd filed Critical Lg Chemical Ltd
Publication of BRPI0411114A publication Critical patent/BRPI0411114A/pt
Publication of BRPI0411114B1 publication Critical patent/BRPI0411114B1/pt
Publication of BRPI0411114B8 publication Critical patent/BRPI0411114B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

solução aquosa estável de eritropoetina humana, não contendo albumina de soro. a presente invenção fornece uma formulação aquosa de eritropoetina humana tendo a estabilidade de armazenamento após um longo período sem albumina de soro, em que a formulação compreende uma quantidade farmaceuticamente eficaz de eritropoetina humana; tensoativo não-iônico, álcool poliídrico, aminoácido neutro e álcool de açúcar como estabilizadores; reagente isotônico; e reagente tampão.
BRPI0411114A 2003-06-10 2004-06-07 solução aquosa estável de eritropoetina humana, não contendo albumina de soro BRPI0411114B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2003-0037060 2003-06-10
KR20030037060 2003-06-10
PCT/KR2004/001358 WO2004108152A1 (en) 2003-06-10 2004-06-07 Stable, aqueous solution of human erythropoietin, not containing serum albumin

Publications (3)

Publication Number Publication Date
BRPI0411114A BRPI0411114A (pt) 2006-07-18
BRPI0411114B1 BRPI0411114B1 (pt) 2020-09-15
BRPI0411114B8 true BRPI0411114B8 (pt) 2021-05-25

Family

ID=36337525

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411114A BRPI0411114B8 (pt) 2003-06-10 2004-06-07 solução aquosa estável de eritropoetina humana, não contendo albumina de soro

Country Status (18)

Country Link
US (1) US8119595B2 (pt)
EP (1) EP1641486B1 (pt)
JP (1) JP4871720B2 (pt)
KR (1) KR100610003B1 (pt)
CN (1) CN1802171B (pt)
AT (1) ATE553747T1 (pt)
AU (1) AU2004244920B2 (pt)
BR (1) BRPI0411114B8 (pt)
CA (1) CA2528988C (pt)
EA (1) EA009676B1 (pt)
ES (1) ES2385888T3 (pt)
MX (1) MXPA05013398A (pt)
NO (1) NO20055747L (pt)
NZ (1) NZ543859A (pt)
PL (1) PL379272A1 (pt)
UA (1) UA82241C2 (pt)
WO (1) WO2004108152A1 (pt)
ZA (1) ZA200509222B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY139088A (en) * 2005-02-21 2009-08-28 Lg Life Sciences Ltd Sustained release composition of protein drug
EP1997505A4 (en) 2006-03-22 2013-02-13 Chugai Pharmaceutical Co Ltd PREPARATION OF A ERYTHROPOETIN SOLUTION
DE102007050165B4 (de) * 2007-10-19 2010-06-17 Stiftung Tierärztliche Hochschule Hannover Stabilisierte Lösung, Verfahren zu deren Herstellung sowie deren Verwendung und Arzneimittel in Form einer stabilisierten Lösung
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
US20120213846A1 (en) * 2008-08-15 2012-08-23 Forest Laboratories Holdings Limited Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration
US8748573B2 (en) * 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
US8829163B2 (en) * 2010-01-19 2014-09-09 Hanmi Science Co., Ltd Liquid formulations for long-acting erythropoietin conjugate
WO2011103311A2 (en) 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc Treatments for gastrointestinal disorders
HRP20192207T1 (hr) 2010-08-11 2020-02-21 Ironwood Pharmaceuticals, Inc. Stabilne formulacije linaklotida
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
HUE032237T2 (en) 2011-08-17 2017-09-28 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
CN107693781B (zh) * 2013-03-13 2021-11-09 巴扎德制药公司 用于眼部递送的嵌合细胞因子制剂
EP2832361A1 (en) * 2013-07-29 2015-02-04 Ipsen Pharma S.A.S. Aqueous sustained release compositions of LHRH analogs
US20180110833A1 (en) * 2015-04-21 2018-04-26 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nerve growth factor composition and powder injection
CN118338910A (zh) * 2021-12-03 2024-07-12 杰科（天津）生物医药有限公司 一种制剂及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS6191131A (ja) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd 医薬品の吸着防止方法および組成物
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
GB9001987D0 (en) * 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
CA2319680C (en) * 1997-02-07 2010-04-20 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
AU5649299A (en) * 1998-09-11 2000-04-03 Chugai Seiyaku Kabushiki Kaisha Protein solution preparation and method for stabilizing the same
ATE401908T1 (de) * 1999-04-09 2008-08-15 Ortho Mcneil Pharm Inc Pharmazeutische zusammensetzungen von erythropoietin
EP1232753B1 (en) * 1999-09-08 2008-03-19 Chugai Seiyaku Kabushiki Kaisha Stable protein solution filled in a container made from a hydrophobic resin and method of stabilizing the same
AU2001236005A1 (en) * 2000-02-29 2001-09-12 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
JP3967594B2 (ja) * 2000-05-15 2007-08-29 エフ．ホフマン−ラ ロシュ アーゲー 新しい薬剤組成物
SI21258A (sl) * 2002-07-17 2004-02-29 LEK farmacevtska dru�ba d.d. Stabilni farmacevtski pripravek, ki vsebuje eritropoietin in poloksamerni poliol

Also Published As

Publication number Publication date
AU2004244920B2 (en) 2009-07-23
BRPI0411114B1 (pt) 2020-09-15
CA2528988C (en) 2012-05-01
JP4871720B2 (ja) 2012-02-08
WO2004108152A1 (en) 2004-12-16
US20070293419A1 (en) 2007-12-20
NO20055747L (no) 2006-03-07
NO20055747D0 (no) 2005-12-05
CN1802171B (zh) 2010-10-13
KR100610003B1 (ko) 2006-08-08
EA009676B1 (ru) 2008-02-28
ATE553747T1 (de) 2012-05-15
NZ543859A (en) 2008-01-31
EP1641486A4 (en) 2008-10-08
HK1093012A1 (en) 2007-02-23
US8119595B2 (en) 2012-02-21
ES2385888T3 (es) 2012-08-02
UA82241C2 (uk) 2008-03-25
CA2528988A1 (en) 2004-12-16
BRPI0411114A (pt) 2006-07-18
EP1641486A1 (en) 2006-04-05
EP1641486B1 (en) 2012-04-18
EA200501789A1 (ru) 2006-06-30
MXPA05013398A (es) 2006-03-09
PL379272A1 (pl) 2006-08-21
JP2007528842A (ja) 2007-10-18
AU2004244920A1 (en) 2004-12-16
ZA200509222B (en) 2006-09-27
KR20040110994A (ko) 2004-12-31
CN1802171A (zh) 2006-07-12

Similar Documents

Publication Publication Date Title
EA200501789A1 (ru) Стабильный водный раствор эритропоэтина человека, не содержащий сывороточного альбумина
NO20043353L (no) Antistoff-inneholdende opplosningsfarmasoytika
WO2006020935A3 (en) Stabilizing formulations
HRP20110094T8 (en) Solid preparation comprising alogliptin and pioglitazone
ES2155043B1 (es) Composiciones farmaceuticas comprendiendo acido pirimidin-5-il(3r, 5s)-3,5-dihidroxihept-6-enoico o una sal suya, su estabilizacion con sal fosfato tribasico y su preparacion.
MXPA03010640A (es) Composiciones pesticidas liquidas estables.
ATE362314T1 (de) Herbizidzusammensetzungen umfassend imidazolinonsäure
AR059964A1 (es) Metodos para reducir la aglomeracion de proteina
MX375672B (es) Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9.
EP1712240A4 (en) STABLE MEDICAL WATER BASED PREPARATION WITH ANTIBODY
DK1372608T3 (da) Medicinske aerosolformuleringer
AR083034A1 (es) ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO
CL2012002948A1 (es) Formulación acuosa estable que comprende proteina almenos 5 mg/ml de proteina cd-rap y un aminoácido cargado.
ATE457977T1 (de) Biguanidderivate
EP1608395A4 (en) ANTICROPE WITH LK8 PROTEIN AS AN ACTIVE SUBSTANCE
DE60316574D1 (de) Stabile augentropfen enthaltend latanoprost als wirkstoff
UA87506C2 (ru) Применение электролита как стабилизатора ингибитора
AR044449A1 (es) Composiciones acuosas desinfectantes y/o bactericidas
DK1272655T3 (da) Stabilisering af meget fölsomme nucleinsyrefarver i vandig oplösning
EA200400751A1 (ru) Применение дезоксипеганина для лечения клинической депрессии
NO20065791L (no) Asyklovir-formuleringer
WO2004075834A3 (en) Stabilized pharmaceutical compositions of safingol and methods of using the same
CA2545880A1 (en) Erythropoietin solution formulation
ATE424399T1 (de) Pharmazeutische zusammensetzungen von risperidon in wässriger lösung
UY27271A1 (es) Composiciones farmacéuticas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25A Requested transfer of rights approved

Owner name: LG CHEM, LTD. (KR)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/06/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2830 DE 01/04/2025 POR TER SIDO INDEVIDA.